GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The settlement, which calls for Gilead to pay the U.S. nearly $177 million and the balance to various states, was approved ...

If you support maintaining the U.S. approach to fighting HIV/AIDS, you should welcome the DOGE review to ensure that programs ...

Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression ...

A former top federal health official who served during President Trump’s first term warned that the drastic cuts to the ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Demonstrators gathered Thursday on the steps of the Department of Health and Human Services (HHS) building for a “die-in” ...

Dolutegravir is recommended by the World Health Organization (WHO) for infants, children and adults and is the preferred HIV ...

Cuts to sexual health clinics could make eliminating new HIV cases in England by 2030 “impossible”, politicians have warned.

A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and ...

An HIV patient in Laredo is sharing his advice with others living with the disease to raise awareness and highlight available ...